Zai Lab/$ZLAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zai Lab
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
Ticker
$ZLAB
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
1,869
Website
Zai Lab Metrics
BasicAdvanced
$4.3B
-
-$2.48
0.95
-
Price and volume
Market cap
$4.3B
Beta
0.95
52-week high
$44.34
52-week low
$16.01
Average daily volume
809K
Financial strength
Current ratio
3.258
Quick ratio
2.642
Long term debt to equity
1.519
Total debt to equity
23.718
Interest coverage (TTM)
-80.56%
Profitability
EBITDA (TTM)
-255.817
Gross margin (TTM)
5.94%
Net profit margin (TTM)
-60.26%
Operating margin (TTM)
-64.09%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-15.50%
Return on equity (TTM)
-32.05%
Valuation
Price to revenue (TTM)
9.371
Price to book
5.16
Price to tangible book (TTM)
5.56
Price to free cash flow (TTM)
-16.413
Free cash flow yield (TTM)
-6.09%
Free cash flow per share (TTM)
-2.35
Growth
Revenue change (TTM)
43.72%
Earnings per share change (TTM)
-29.08%
3-year revenue growth (CAGR)
34.76%
3-year earnings per share growth (CAGR)
-24.85%
What the Analysts think about Zai Lab
Analyst ratings (Buy, Hold, Sell) for Zai Lab stock.
Bulls say / Bears say
Zai Lab's collaboration with Seagen and Genmab on Tivdak has shown positive phase 3 trial results, meeting its primary endpoint in treating metastatic cervical cancer, which could lead to accelerated FDA approval and expanded market opportunities. (fool.com)
The company has received Fast Track designation from the U.S. FDA for ZL-1310, a DLL3-targeted antibody-drug conjugate for extensive-stage small cell lung cancer, potentially expediting its development and approval process. (stocktitan.net)
Zai Lab's strategic partnership with Mirati Therapeutics to develop and commercialize adagrasib in Greater China, with an upfront payment of $65 million and potential milestone payments up to $273 million, positions the company to expand its oncology portfolio and revenue streams. (stocktitan.net)
Insider selling activity, including the CEO's sale of 50,000 shares, may raise concerns about internal confidence in the company's future performance. (marketbeat.com)
The company's recent follow-on public offering of 7,843,137 American Depositary Shares to raise $200 million could lead to share dilution, potentially impacting existing shareholders' value. (nasdaq.com)
Despite positive trial results, the market's lukewarm reaction to the TTFields therapy for non-small cell lung cancer suggests skepticism about its commercial viability and potential revenue impact. (fool.com)
Data summarised monthly by Lightyear AI. Last updated on 13 Jul 2025.
Zai Lab Financial Performance
Revenues and expenses
Zai Lab Earnings Performance
Company profitability
Zai Lab News
AllArticlesVideos
Zai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025
Business Wire·3 weeks ago
Zai Lab Announces Positive Topline Phase 3 Results for Bemarituzumab in Fibroblast Growth Factor Receptor 2b (FGFR2b) Positive First-Line Gastric Cancer
Business Wire·1 month ago
Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zai Lab stock?
Zai Lab (ZLAB) has a market cap of $4.3B as of August 01, 2025.
What is the P/E ratio for Zai Lab stock?
The price to earnings (P/E) ratio for Zai Lab (ZLAB) stock is 0 as of August 01, 2025.
Does Zai Lab stock pay dividends?
No, Zai Lab (ZLAB) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Zai Lab dividend payment date?
Zai Lab (ZLAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Zai Lab?
Zai Lab (ZLAB) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.